Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Multiple Myeloma Advanced 2026

Mohamad Mohty

穆罕默德·莫蒂

MD, PhD

🏢Hôpital Saint-Antoine, Sorbonne University, Paris(巴黎圣安托万医院,索邦大学)🌐France

Professor of Hematology; Head, Hematology and Cellular Therapy Department血液学教授;血液学与细胞治疗科主任

74
h-index
2
Key Papers
4
Awards
2
Key Contributions

👥Biography 个人简介

Mohamad Mohty, MD, PhD is Professor of Hematology at Sorbonne University and Head of Hematology at Hôpital Saint-Antoine. Past President of the European Society for Blood and Marrow Transplantation (EBMT), he is a leading authority on autologous transplantation in myeloma, post-ASCT maintenance optimization, and novel consolidation strategies integrating immunotherapy.

Share:

🧪Research Fields 研究领域

Autologous Stem Cell Transplantation自体干细胞移植
Post-ASCT Maintenance移植后维持治疗
GvHD Prevention移植物抗宿主病预防
Myeloma Consolidation Strategies骨髓瘤巩固策略
European Bone Marrow Transplantation (EBMT)欧洲骨髓移植协会

🎓Key Contributions 主要贡献

Post-ASCT Maintenance Optimization

Led European trials defining optimal post-transplant maintenance in myeloma, including lenalidomide and novel agent combinations, and guided EBMT consensus guidelines on transplant indications and sequencing with new immunotherapies.

EBMT Registry and Transplant Outcomes Research

As EBMT President, oversaw the world's largest transplant outcomes database, enabling landmark real-world analyses of ASCT trends, second transplants, and integration of CAR-T in the post-transplant myeloma setting.

Representative Works 代表性著作

[1]

Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma (IKEMA)

The Lancet (2021)

Phase III trial demonstrating isatuximab-Kd significantly improved PFS over Kd in relapsed myeloma, supporting addition of anti-CD38 antibody to carfilzomib backbone.

[2]

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation

The Lancet (2010)

IFM 2006-01 trial establishing VTD superiority over TD as pre-transplant induction in NDMM, shaping European transplant-eligible treatment standards for a decade.

🏆Awards & Recognition 奖项与荣誉

🏆EBMT Presidential Award
🏆French Society of Hematology (SFH) Grand Prix de Recherche
🏆Sorbonne University Research Excellence Award
🏆European Hematology Association (EHA) Senior Investigator Recognition

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 穆罕默德·莫蒂 的研究动态

Follow Mohamad Mohty's research updates

留下邮箱,当我们发布与 Mohamad Mohty(Hôpital Saint-Antoine, Sorbonne University, Paris)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment